265 related articles for article (PubMed ID: 32468335)
1. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients.
Cho H; Lee S; Sim SH; Park IH; Lee KS; Kwak MH; Kim HJ
Breast Cancer Res Treat; 2020 Jul; 182(2):333-343. PubMed ID: 32468335
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Swain SM; Ewer MS; Viale G; Delaloge S; Ferrero JM; Verrill M; Colomer R; Vieira C; Werner TL; Douthwaite H; Bradley D; Waldron-Lynch M; Kiermaier A; Eng-Wong J; Dang C;
Ann Oncol; 2018 Mar; 29(3):646-653. PubMed ID: 29253081
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
Banke A; Fosbøl EL; Ewertz M; Videbæk L; Dahl JS; Poulsen MK; Cold S; Jensen MB; Gislason GH; Schou M; Møller JE
JACC Heart Fail; 2019 Mar; 7(3):217-224. PubMed ID: 30819377
[TBL] [Abstract][Full Text] [Related]
4. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.
Conte P; Frassoldati A; Bisagni G; Brandes AA; Donadio M; Garrone O; Piacentini F; Cavanna L; Giotta F; Aieta M; Gebbia V; Molino A; Musolino A; Ferro A; Maltoni R; Danese S; Zamagni C; Rimanti A; Cagossi K; Russo A; Pronzato P; Giovanardi F; Moretti G; Lombardo L; Schirone A; Beano A; Amaducci L; Bajardi EA; Vicini R; Balduzzi S; D'Amico R; Guarneri V
Ann Oncol; 2018 Dec; 29(12):2328-2333. PubMed ID: 30219886
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?
De Santis MC; Bonfantini F; Di Salvo F; Fiorentino A; Riboldi VM; Di Cosimo S; Bianchi GV; Gennaro M; Cosentino V; Sant M; Pignoli E; Valdagni R; Lozza L
Clin Breast Cancer; 2018 Jun; 18(3):e363-e371. PubMed ID: 28958838
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy.
Upshaw JN; Finkelman B; Hubbard RA; Smith AM; Narayan HK; Arndt L; Domchek S; DeMichele A; Fox K; Shah P; Clark A; Bradbury A; Matro J; Adusumalli S; Carver JR; Ky B
JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 2):198-210. PubMed ID: 31542526
[TBL] [Abstract][Full Text] [Related]
7. New Cardiac Abnormalities After Radiotherapy in Breast Cancer Patients Treated With Trastuzumab.
Nack E; Koffer PP; Blumberg CS; Leonard KL; Huber KE; Fenton MA; Dizon DS; Wazer DE; Hepel JT
Clin Breast Cancer; 2020 Jun; 20(3):246-252. PubMed ID: 32067901
[TBL] [Abstract][Full Text] [Related]
8. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
9. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.
Putt M; Hahn VS; Januzzi JL; Sawaya H; Sebag IA; Plana JC; Picard MH; Carver JR; Halpern EF; Kuter I; Passeri J; Cohen V; Banchs J; Martin RP; Gerszten RE; Scherrer-Crosbie M; Ky B
Clin Chem; 2015 Sep; 61(9):1164-72. PubMed ID: 26220066
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
13. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
[TBL] [Abstract][Full Text] [Related]
16. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
18. Familial breast cancer, pregnancy and cardiotoxicity associated with the use of doxorubicin and reaction with trastuzumab.
Valente PMS; Gomes MCB; Martins WA; Castilho SR
J Oncol Pharm Pract; 2022 Dec; 28(8):1893-1897. PubMed ID: 35321591
[TBL] [Abstract][Full Text] [Related]
19. Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.
Wittayanukorn S; Qian J; Westrick SC; Billor N; Johnson B; Hansen RA
Am J Clin Oncol; 2018 Sep; 41(9):909-918. PubMed ID: 28537988
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide association study of genetic variants related to anthracycline-induced cardiotoxicity in early breast cancer.
Park B; Sim SH; Lee KS; Kim HJ; Park IH
Cancer Sci; 2020 Jul; 111(7):2579-2587. PubMed ID: 32378780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
